Failed pivotal study? You can still have breakthrough therapy status — FDA signals to Resverlogix
A small Canadian biotechnology company has convinced the FDA to reward its sole experimental drug breakthrough therapy status as a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
